Requested symbol wasn't found

U.S. Markets closed

(VSCP)


NasdaqCM . Currency in USD
Add to watchlist
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire7 months ago

    VirtualScopics, Inc. Board Determines Gastineau Partners Proposal Not Reasonably Expected to Lead to a Superior Company Proposal

    ROCHESTER, N.Y., May 9, 2016 /PRNewswire/ -- VirtualScopics, Inc. (VSCP), a leading provider of clinical trial imaging solutions, announced today that its Board of Directors, in consultation with its legal and financial advisors, has determined that an unsolicited proposal from a group identifying itself as Gastineau Partners, LLC, to acquire an uncertain number of shares of the Company's outstanding common and preferred stock and purchase newly issued preferred stock at an undetermined price and unspecified rights, preferences and privileges, would not reasonably be expected to lead to a Superior Company Proposal under the terms of its merger agreement with BioTelemetry, Inc. (NASDAQ:BEAT). The Company received the proposal from Gastineau Partners on May 5, 2016, the same day in which Gastineau Partners issued a press release announcing the offer.  The Company then contacted Gastineau Partners' representatives solely to clarify the terms of the proposal.  The group admitted it does not have committed financing for the purchase at this time.  Additionally, under the terms of the proposal and through supplemental information provided by Gastineau Partners, the group would not be bound to acquire 75% or more of the voting power of the Company's outstanding capital stock as required for it to be a Superior Company Proposal under the BioTelemetry merger agreement.  Furthermore, the price, rights, privileges and preferences of the newly issued preferred stock to be purchased would be decided only after tenders of common stock were completed.  The group would not commit to signing a definitive agreement in less than 45 days.

  • VirtualScopics, Inc. :VSCP-US: Earnings Analysis: Q4, 2015 By the Numbers
    Capital Cube8 months ago

    VirtualScopics, Inc. :VSCP-US: Earnings Analysis: Q4, 2015 By the Numbers

    Click here to see latest analysisVirtualScopics, Inc. reports financial results for the quarter ended December 31, 2015.We analyze the earnings along side the following peers of VirtualScopics, Inc. – Becton, Dickinson and Company, Arrhythmia Research Technology, Inc., Enzo Biochem, Inc., Bioanalytical Systems, Inc., NeoGenomics, Inc., Laboratory Corporation of America Holdings and CombiMatrix Corporation (BDX-US, HRT-US, […] (Read more...) The post VirtualScopics, Inc. :VSCP-US: Earnings Analysis: Q4, 2015 By the Numbers appeared first on CapitalCube.

  • PR Newswire8 months ago

    VirtualScopics, Inc. Cancels Conference Call Due To Recent Announcement Of The Definitive Agreement With BioTelemetry, Inc.

    ROCHESTER, N.Y., March 29, 2016 /PRNewswire/ -- VirtualScopics, Inc. (VSCP), a leading provider of clinical trial imaging solutions, today announced it will not hold its conference call, or provide its webcast, previously scheduled for Wednesday, March 30, 2016 at 8:30 a.m. ET. On March 25, 2016, VirtualScopics announced that it had entered into a definitive agreement with BioTelemetry, Inc. (BEAT) whereby BioTelemetry will acquire VirtualScopics.